Abstracts tagged "interstitial lung disease"

Abstract Number: 708 • 2019 ACR/ARP Annual Meeting
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Yannick Allanore¹, Dinesh Khanna ², Elizabeth Volkmann ³, Christian Stock ⁴, Martina Gahlemann ⁵, Nils Schoof ⁶, Oliver Distler ⁷ and Toby Maher ⁸, ¹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: Mean change in forced vital capacity percent predicted (FVC %pred) is a common endpoint in the assessment of treatment-related outcomes in patients with interstitial…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 1654 • 2019 ACR/ARP Annual Meeting
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann ², Carrie Richardson ³, Kimberly Koloms ², Gerald Rouleau ², David Aaby ², Julia (Jungwha) Lee ⁴, Jane Dematte ², Rishi Agrawal ², Xiaoping Wu ⁵, Rowland Chang ⁴ and Monique Hinchcliff ⁶, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Chicago, ³Rush University, Chicago, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵New York Presbyterian/Weill Cornell, New York, ⁶Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT
Background/Purpose: Prior work has shown that Scl-70 positive autoantibody status and baseline c-reactive protein (CRP) are associated with more rapid pulmonary function decline in patients…
Abstract Number: 2345 • 2019 ACR/ARP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
C. Fernández-Díaz¹, Rafael Melero ², Javier Loricera ³, Santos Castañeda ⁴, Francisco Ortiz-Sanjuán ⁵, I. Casafont-Solé ⁶, Carmen carrasco-Cubero ⁷, A. Juan-Mas ⁸, Raquel Almodovar-Gonzalez ⁹, S. Rodriguez-Garcia ¹⁰, R. Castellanos ¹¹, O. Maiz-Alonso ¹², C. Aguilera-Cros ¹³, I. Cabezas-rodriguéz ¹⁴, EC Cervantes ¹⁵, M. Moreno ¹⁶, L. Arboleya ¹⁷, C. Montagut ¹⁸, Patricia Carreira ¹⁹, C. Ojeda-Garcia ²⁰, Gema Bonilla ²¹, T. Perez-Sandoval ²², P. Vela ²³, JL Andreu ²⁴, Susana Romero-Yuste ²⁵, A. Urruticoechea-Arana ²⁶, E. Salgado-Pérez ²⁷, Cristina Hidalgo ²⁸, Javier Narváez ²⁹, E. Raya ³⁰, MJ. Moreno-Ramos ³¹, P. Morales-Garrido ³², L. Pérez-alba ³³, Carlos Fernández-López ³⁴, Ignacio Villa ³⁵, Noelia Álvarez-Rivas ³⁶, Juan María Blanco-Madrigal ³⁷, JR Jimenez-Aberasturi ³⁸, A. Perez-Linaza ³⁹, N. Del-val-del-amo ⁴⁰, Sabela Fernández ⁴¹, A. García-valle ⁴², C.A. Peralta-Ginés ⁴³, A. Garcia-Aparicio ⁴⁴, L. Exposito-pérez ⁴⁵, N. Mena-Vazquez ⁴⁶, R. López-Sánchez ⁴⁷, B. Garcia-magallon ⁴⁸, Miguel Angel González-Gay ⁴⁹ and Ricardo Blanco ⁵⁰, ¹HU Vinalopo, Madrid, Madrid, Spain, ²Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁶HU German Trias i pujol, BAacelona, ⁷CHU de Badajoz, Badajoz, Spain, ⁸H Son Llázer, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁰HU. Clinic, Barcelona, ¹¹Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ¹²HU Donostia, Donostia, Spain, ¹³hospital virgen del rocio, Sevilla, Spain, ¹⁴HU. Río Hortega, Valladolid, Spain, ¹⁵HU Santiago de compostela, Santiago, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Spain, ¹⁷Hospital Central Asturias, OViedo, ¹⁸HCU Valladolid, Valladolid, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰HU Virgen de la Macarena, Sevilla, ²¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ²²HU León, León, Spain, ²³Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ²⁴HU Puerta del Hierro, Madrid, ²⁵Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ²⁶HU Can Misses, Ibiza, Spain, ²⁷C.H Ourense, Ourense, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁹Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³⁰Hospital San Cecilio, Granada, Andalucia, Spain, ³¹HU Arrixaca, Murcia, Spain, ³²Hospital San Cecilio, Granada, Spain, ³³HU San Cecilio, Granada, Spain, ³⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ³⁵Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³⁷Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³⁸HU Araba, Vitoria, Spain, ³⁹HU Puerta del Mar, Cadiz, ⁴⁰HU Navarra, Pamplona, Spain, ⁴¹Hospital Universitario San Agustín, Avilés, Asturias, Spain, ⁴²Rheumatology Department. Hospital Rio Carrión, Palencia, Spain, ⁴³HU Lozano Blesa, Zaragoza, ⁴⁴H Virgen de la salud, Toledo, Spain, ⁴⁵HU Canarias, Tenerife, Spain, ⁴⁶HU Malaga., Malaga, ⁴⁷Hospital Negrin, Tenerife, ⁴⁸H Huesca, HUesca, ⁴⁹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵⁰Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor…
Abstract Number: 1734 • 2018 ACR/ARHP Annual Meeting
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Vincent Sobanski¹, Jeska de Vries-Bouwstra², Anna-Maria Hoffmann-Vold³, Dörte Huscher⁴, Margarida Alves⁵, Marco Matucci-Cerinic⁶, Gabriela Riemekasten⁷, Mengtao Li⁸, Gabriele Valentini⁹, László Czirják¹⁰, Otylia Kowal-Bielecka¹¹, Yannick Allanore¹², Nils Schoof⁵ and Oliver Distler¹³, ¹Department of Internal Medicine and Clinical Immunology, University of Lille, Lille, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo University Hospital, Oslo, Norway, ⁴Charité – Universitaetsmedizin Berlin and Berlin Institute of Health, Berlin, Germany, ⁵Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁷Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ⁸Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁹Department of Rheumatology, Second University of Naples, Napoli, Italy, ¹⁰Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ¹¹Department of Rheumatology and Internal Medicine, Medical University of Białystok, Białystok, Poland, ¹²Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ¹³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of morbidity and mortality in patients with SSc. However, the impact of changes in…
Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Sara Sabbagh¹, Iago Pinal-Fernandez¹, Takayuki Kishi², Ira N. Targoff³, Frederick W. Miller², Lisa G. Rider² and Andrew Mammen^1,4, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…
Abstract Number: 2257 • 2018 ACR/ARHP Annual Meeting
Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases
Kristina E.N. Clark¹, Huw Beynon², Christopher P. Denton³ and Voon H. Ong⁴, ¹Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in both sarcoidosis (up to 90%) and autoimmune rheumatic diseases (ARDs). Case reports have suggested distinct clinical manifestations when sarcoidosis…
Abstract Number: 375 • 2018 ACR/ARHP Annual Meeting
Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
Johannes Knitza, Hannah Schenker, Georg Schett and Jörg Distler, Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Antisynthetase Syndrome is a rare and severe autoimmune inflammatory disease that is associated with autoimmunity against aminoacyl-tRNA synthetase and clinical signs of arthritis, myositis…
Abstract Number: 2422 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
Stephanie L. Giattino, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Currently published data regarding pregnancy outcomes in patients with interstitial lung disease (ILD) related to autoimmune disease and sarcoidosis is limited, with widely variant…
Abstract Number: 384 • 2018 ACR/ARHP Annual Meeting
Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
Bret Sohn¹, Narender Annapureddy², Rosemarie Dudenhofer³, April Barnado¹, Leslie Crofford¹ and Erin Wilfong⁴, ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Division of Rheumatology and Immunology, Vanderbilt Unversity Medical Center, Nashville, TN
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in connective tissue diseases (CTDs). The purpose of this study is to…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].